Elite Pharma Inc (ELTP) 0.4330 $ELTP
Fed Shows Confidence in Market with Cut in Bond Buying Stimulus
PR Newswire Europe - Thu May 01, 6:33AM CDT
LONDON, May 1, 2014 /PRNewswire/ --
FDA Approves Clinical Trial of BrainStorm Cell Therapeutics' ALS Treatment
ACCESSWIRE - Tue Apr 29, 9:05AM CDT
BrainStorm Cell Therapeutics' (OTCQB: BCLI) stock volume skyrocketed Apr. 28, with 3,714,379 shares changing hands, more than 5 times its three-month average volume of 718,105 shares.
Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology
GlobeNewswire - Tue Apr 22, 6:41AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
(OTCBB:ELTP) announced today the issuance of U.S. Patent No. 8,703,186 titled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof". This patent expands the intellectual property for the Company's opioid abuse deterrent technology. Elite now has three US patents and one Canadian patent issued in this area with additional patents pending in the U.S., Canada and Europe.
Limitless Venture Group Settles $163,391 Note with Beaufort Capital Partners
ACCESSWIRE - Wed Apr 16, 9:07AM CDT
Limitless Venture Group Inc.'s (OTCPINK: LVGI) announced that the company and a third- party debt holder Beaufort Capital Partners reached an amicable settlement regarding an outstanding note which had essentially floorless convertible terms attached.
Elite Pharmaceuticals to Receive up to 40 Million from Lincoln Park Capital Fund
ACCESSWIRE - Tue Apr 15, 9:01AM CDT
Elite Pharmaceuticals Inc. (OTCBB: ELTP) announced Apr. 14 that it has entered into a common stock purchase agreement with Lincoln Park Capital Fund LLC ("LPC" , a Chicago-based institutional investor for up to $40 million.
Elite Pharmaceuticals, Inc. Secures Funding Commitment of Up to $40 Million From Lincoln Park Capital Fund, LLC
GlobeNewswire - Mon Apr 14, 6:30AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP) announced today that it has entered into a common stock purchase agreement with Lincoln Park Capital Fund, LLC ("LPC" , a Chicago-based institutional investor for up to $40 Million. Proceeds from the transaction will be used to develop the Company's pipeline of products, including the abuse resistant opioids, and for general corporate purposes.
Elite Pharmaceuticals Appoints Barbara Ellison as Vice President of Quality Operations and Regulatory Affairs
GlobeNewswire - Thu Mar 27, 11:15AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP) today announced that it has created the position of Vice President, Quality Operations & Regulatory Affairs and has hired industry veteran, Barbara Ellison, to fill that role. Ms. Ellison has extensive experience in quality assurance, regulatory compliance, validation, performance optimization and quality control. Ms. Ellison will have overall responsibility for Elite's quality and regulatory functions including the Company's Quality Assurance and Compliance group and the Analytics and Quality Control group. Ms. Ellison will serve as a member of Elite's senior leadership team, reporting directly to Nasrat Hakim, Elite's President and Chief Executive Officer.
OTC Daily Alert Stock Watch - Elite Pharmaceuticals, Inc. (OTCQB: ELTP)
WorldStockWire - Tue Mar 25, 7:00AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Elite Pharmaceuticals submits site transfer application of Isradipine under FDA's CBE-30
M2 - Tue Mar 25, 5:55AM CDT
Controlled release products company Elite Pharmaceuticals (OTC BB:ELTP) reported on Monday the submission of a supplemental application with the US Food and Drug Administration (FDA) for the site transfer of manufacturing for Isradipine 2.5 mg and 5 mg tablets to its Northvale facility.
Elite Pharmaceuticals Announces Supplemental Application for Site Transfer of Isradipine
GlobeNewswire - Mon Mar 24, 7:05AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP) today announced that on March 21, 2014, the Company filed a Changes Being Effected in 30 Days (CBE-30) supplemental application with the U.S. Food and Drug Administration (FDA) for the site transfer of manufacturing for Isradipine 2.5 mg and 5 mg tablets to Elite's Northvale facility.
Applied Materials Named a 2014 World's Most Ethical Company; KeyCorp Reported 2014 Company Run Stress Test Results and Process
ACCESSWIRE - Thu Mar 20, 11:29PM CDT
KeyCorp. (NYSE: KEY) - For an in-depth report on KeyCorp. follow: www.BullTrends.com/stockquote/KEY
Elite Pharmaceuticals awarded abuse deterrent technology patent in Canada, reflecting a rise in its intellectual property protection
M2 - Tue Mar 11, 6:09AM CDT
Controlled release drug products company Elite Pharmaceuticals (OTC BB:ELTP) reported on Monday the receipt of the Canadian Patent Number 2,521,655 titled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof" in Canada.
Elite Pharmaceuticals Expands Abuse Deterrent Technology Patent Portfolio Internationally
GlobeNewswire - Mon Mar 10, 6:47AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP) today announced the expansion of intellectual property protection surrounding the Company's abuse deterrent technology with the issuance of Canadian Patent Number 2,521,655 titled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof". This patent issuance expands the scope and reach of Elite's patent estate internationally. Elite has additional patents pending in the U.S., Canada and Europe.
Elite Pharmaceuticals Reports Successful Pivotal Bioequivalence Study for Abuse Deterrent Product ELI-200
GlobeNewswire - Wed Mar 05, 6:30AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP) announced today successful results from a pivotal bioequivalence study initiated in January 2014 for Elite's undisclosed abuse deterrent opioid product, ELI-200. The study results demonstrated Elite's product is bioequivalent to the branded drug based on pharmacokinetic measures including peak concentration (Cmax) and area under the curve (AUC) for opioid blood plasma levels. The study was a single dose, open label, partially randomized, three-way cross over study in healthy volunteers with 42 subjects under fasted conditions and 38 subjects under fed conditions.
Elite Pharmaceuticals Reports Results of Pilot Bioequivalence Study for ELI-201
GlobeNewswire - Tue Feb 18, 6:00AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" ("Elite" (OTCBB:ELTP) announced today successful results from a pilot bioequivalence study initiated in December 2013 for ELI-201, a twice-daily opioid abuse deterrent oxycodone product with abuse deterrent technology. Three different twice daily formulations developed by Elite were tested in the study. The study results demonstrate that all formulations in the study were bioequivalent to the reference drug based on pharmacokinetic measures including peak plasma concentration (Cmax) and area under the curve (AUC) for oxycodone blood plasma levels. The study was a single dose, open label, randomized, four period, four treatment, cross over study in 16 healthy volunteers under fasted conditions.
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2014
GlobeNewswire - Fri Feb 14, 8:49AM CST
Revenues Increase by 154%, Product Development Accelerating
Prolexic Publishes Infographic on Largest Attacks Mitigated in 2013
M2 - Fri Feb 14, 8:07AM CST
Prolexic Technologies, the global leader in Distributed Denial of Service (DDoS) protection services, today published a new infographic summarizing the statistics about the largest DDoS attacks it mitigated in each quarter of 2013.
Elite Pharmaceuticals, Inc. to Host Third Quarter Business Update Call on February 18, 2014
GlobeNewswire - Mon Feb 10, 2:27PM CST
Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral sustained and controlled release product formulations and generics with high barriers to entry, announced today that management will host a conference call to provide a quarterly business update at 3:00 PM ET on Tuesday, February 18, 2014. Company executives will also conduct a question and answer session following their remarks.
Fed Shows Confidence in Market with Cut in Bond Buying Stimulus
PR Newswire Europe - Thu May 01, 6:33AM CDT
LONDON, May 1, 2014 /PRNewswire/ --
FDA Approves Clinical Trial of BrainStorm Cell Therapeutics' ALS Treatment
ACCESSWIRE - Tue Apr 29, 9:05AM CDT
BrainStorm Cell Therapeutics' (OTCQB: BCLI) stock volume skyrocketed Apr. 28, with 3,714,379 shares changing hands, more than 5 times its three-month average volume of 718,105 shares.
Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology
GlobeNewswire - Tue Apr 22, 6:41AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
(OTCBB:ELTP) announced today the issuance of U.S. Patent No. 8,703,186 titled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof". This patent expands the intellectual property for the Company's opioid abuse deterrent technology. Elite now has three US patents and one Canadian patent issued in this area with additional patents pending in the U.S., Canada and Europe. Limitless Venture Group Settles $163,391 Note with Beaufort Capital Partners
ACCESSWIRE - Wed Apr 16, 9:07AM CDT
Limitless Venture Group Inc.'s (OTCPINK: LVGI) announced that the company and a third- party debt holder Beaufort Capital Partners reached an amicable settlement regarding an outstanding note which had essentially floorless convertible terms attached.
Elite Pharmaceuticals to Receive up to 40 Million from Lincoln Park Capital Fund
ACCESSWIRE - Tue Apr 15, 9:01AM CDT
Elite Pharmaceuticals Inc. (OTCBB: ELTP) announced Apr. 14 that it has entered into a common stock purchase agreement with Lincoln Park Capital Fund LLC ("LPC"
, a Chicago-based institutional investor for up to $40 million. Elite Pharmaceuticals, Inc. Secures Funding Commitment of Up to $40 Million From Lincoln Park Capital Fund, LLC
GlobeNewswire - Mon Apr 14, 6:30AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
(OTCBB:ELTP) announced today that it has entered into a common stock purchase agreement with Lincoln Park Capital Fund, LLC ("LPC" , a Chicago-based institutional investor for up to $40 Million. Proceeds from the transaction will be used to develop the Company's pipeline of products, including the abuse resistant opioids, and for general corporate purposes. Elite Pharmaceuticals Appoints Barbara Ellison as Vice President of Quality Operations and Regulatory Affairs
GlobeNewswire - Thu Mar 27, 11:15AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
(OTCBB:ELTP) today announced that it has created the position of Vice President, Quality Operations & Regulatory Affairs and has hired industry veteran, Barbara Ellison, to fill that role. Ms. Ellison has extensive experience in quality assurance, regulatory compliance, validation, performance optimization and quality control. Ms. Ellison will have overall responsibility for Elite's quality and regulatory functions including the Company's Quality Assurance and Compliance group and the Analytics and Quality Control group. Ms. Ellison will serve as a member of Elite's senior leadership team, reporting directly to Nasrat Hakim, Elite's President and Chief Executive Officer. OTC Daily Alert Stock Watch - Elite Pharmaceuticals, Inc. (OTCQB: ELTP)
WorldStockWire - Tue Mar 25, 7:00AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Elite Pharmaceuticals submits site transfer application of Isradipine under FDA's CBE-30
M2 - Tue Mar 25, 5:55AM CDT
Controlled release products company Elite Pharmaceuticals (OTC BB:ELTP) reported on Monday the submission of a supplemental application with the US Food and Drug Administration (FDA) for the site transfer of manufacturing for Isradipine 2.5 mg and 5 mg tablets to its Northvale facility.
Elite Pharmaceuticals Announces Supplemental Application for Site Transfer of Isradipine
GlobeNewswire - Mon Mar 24, 7:05AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
(OTCBB:ELTP) today announced that on March 21, 2014, the Company filed a Changes Being Effected in 30 Days (CBE-30) supplemental application with the U.S. Food and Drug Administration (FDA) for the site transfer of manufacturing for Isradipine 2.5 mg and 5 mg tablets to Elite's Northvale facility. Applied Materials Named a 2014 World's Most Ethical Company; KeyCorp Reported 2014 Company Run Stress Test Results and Process
ACCESSWIRE - Thu Mar 20, 11:29PM CDT
KeyCorp. (NYSE: KEY) - For an in-depth report on KeyCorp. follow: www.BullTrends.com/stockquote/KEY
Elite Pharmaceuticals awarded abuse deterrent technology patent in Canada, reflecting a rise in its intellectual property protection
M2 - Tue Mar 11, 6:09AM CDT
Controlled release drug products company Elite Pharmaceuticals (OTC BB:ELTP) reported on Monday the receipt of the Canadian Patent Number 2,521,655 titled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof" in Canada.
Elite Pharmaceuticals Expands Abuse Deterrent Technology Patent Portfolio Internationally
GlobeNewswire - Mon Mar 10, 6:47AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
(OTCBB:ELTP) today announced the expansion of intellectual property protection surrounding the Company's abuse deterrent technology with the issuance of Canadian Patent Number 2,521,655 titled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof". This patent issuance expands the scope and reach of Elite's patent estate internationally. Elite has additional patents pending in the U.S., Canada and Europe. Elite Pharmaceuticals Reports Successful Pivotal Bioequivalence Study for Abuse Deterrent Product ELI-200
GlobeNewswire - Wed Mar 05, 6:30AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
(OTCBB:ELTP) announced today successful results from a pivotal bioequivalence study initiated in January 2014 for Elite's undisclosed abuse deterrent opioid product, ELI-200. The study results demonstrated Elite's product is bioequivalent to the branded drug based on pharmacokinetic measures including peak concentration (Cmax) and area under the curve (AUC) for opioid blood plasma levels. The study was a single dose, open label, partially randomized, three-way cross over study in healthy volunteers with 42 subjects under fasted conditions and 38 subjects under fed conditions. Elite Pharmaceuticals Reports Results of Pilot Bioequivalence Study for ELI-201
GlobeNewswire - Tue Feb 18, 6:00AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
("Elite" (OTCBB:ELTP) announced today successful results from a pilot bioequivalence study initiated in December 2013 for ELI-201, a twice-daily opioid abuse deterrent oxycodone product with abuse deterrent technology. Three different twice daily formulations developed by Elite were tested in the study. The study results demonstrate that all formulations in the study were bioequivalent to the reference drug based on pharmacokinetic measures including peak plasma concentration (Cmax) and area under the curve (AUC) for oxycodone blood plasma levels. The study was a single dose, open label, randomized, four period, four treatment, cross over study in 16 healthy volunteers under fasted conditions. Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2014
GlobeNewswire - Fri Feb 14, 8:49AM CST
Revenues Increase by 154%, Product Development Accelerating
Prolexic Publishes Infographic on Largest Attacks Mitigated in 2013
M2 - Fri Feb 14, 8:07AM CST
Prolexic Technologies, the global leader in Distributed Denial of Service (DDoS) protection services, today published a new infographic summarizing the statistics about the largest DDoS attacks it mitigated in each quarter of 2013.
Elite Pharmaceuticals, Inc. to Host Third Quarter Business Update Call on February 18, 2014
GlobeNewswire - Mon Feb 10, 2:27PM CST
Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral sustained and controlled release product formulations and generics with high barriers to entry, announced today that management will host a conference call to provide a quarterly business update at 3:00 PM ET on Tuesday, February 18, 2014. Company executives will also conduct a question and answer session following their remarks.
